# Morphic Holding

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/morphic-holding

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.morphictx.com
- Total disclosed funding: $132M
- Latest round: Series B (Sep 25, 2018)
- Investors on record: 7

## About

Morphic Holding, Inc. is a biopharmaceutical company based in the U.S. that specializes in the development of innovative therapies targeting chronic diseases through its proprietary integrin platform.Founded in 2014 and headquartered in Waltham, Massachusetts, Morphic Holding, Inc. focuses on advancing integrin-based therapeutics. The company underwent significant growth, culminating in a TRADE SALE, where it raised USD 3,200.00 mn, primarily from Eli Lilly and Company. Morphic has completed 5 deals, with its most recent funding round occurring on March 2, 2021. The founder, Timothy Springer, has a notable history in the biopharmaceutical sector, contributing to several prior ventures. The company has raised a total of USD 3,200.00 mn since its inception, indicating robust investment interest.Morphic Holding, Inc. is focused on developing oral integrin therapies aimed at treating chronic diseases such as inflammatory bowel disease. Its product candidates are designed to offer advanced treatment options that address significant unmet medical needs in various therapeutic areas. The company's innovative approach enables it to cater to a wide range of health conditions and represents a pivotal shift in biopharmaceutical offerings, particularly in the realm of biologics and gene therapies.In the most recent fiscal year of 2022, Morphic Holding, Inc. reported revenue of USD 70.81 mn, alongside an EBITDA of USD -61.59 mn, highlighting the financial dynamics as the company continues its development efforts.Morphic Holding, Inc. plans to utilize its recent funding from the TRADE SALE to drive research and development of its product candidates, including initiating IND-enabling and clinical studies. The company is also exploring expansion into international markets, targeting Europe and Asia for potential growth by 2023. The recent capital influx will support the development and manufacturing processes essential for bringing new products to market, showcasing the firm’s commitment to advancing its therapeutic portfolio.

## Funding rounds

- Series B, Sep 25, 2018, $80M — Novo Holdings, Invus [DUP], Omega Funds, EcoR1 Capital
- Series A, Jun 30, 2016, $52M — SR One, Omega Funds, Pfizer Venture Investments, AbbVie Ventures

## Investors

- SR One (https://capitalatlas.ai/funds/sr-one) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- Novo Holdings — Series B
- Invus [DUP] — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B